We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

IBTA:NYSEIbotta, Inc. Analysis

Data as of 2026-05-19 - not real-time

$32.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Ibotta, Inc. trades around $32, comfortably above its recent support of $28.5 but still below the 20‑day SMA of $34.6, indicating a near‑term price cushion yet lingering upside potential. Technicals show a bullish trend direction but a bearish MACD divergence and a neutral RSI near 44, suggesting momentum is waning. Volume is increasing, which supports the recent price gains, while the 30‑day volatility of roughly 46% signals a highly erratic price environment. Fundamentally, the company posted a modest revenue decline of 2.5% and negative operating margins, yet cash flow remains positive with $105.8 M operating cash and $63.7 M free cash, and the balance sheet is strong with $164.6 M cash versus $25.3 M debt. Forward earnings estimates are positive ($1.78 EPS) and the DCF fair value of $41.5 implies a modest upside of about 3½%, while the forward P/E of 18 is well below the industry average of 38, positioning the stock as relatively cheap. Recent news highlights a strategic partnership extension with the Denver Nuggets and a buyback program framed as a bullish signal, adding a layer of shareholder‑friendly activity. Overall, the stock sits at a crossroads where technical softness meets valuation comfort and solid liquidity, making it a candidate for cautious accumulation rather than aggressive speculation.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish MACD histogram indicating weakening momentum
  • Price still above key support level
  • High short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • DCF fair value above current price suggesting upside
  • Positive forward EPS and forward P/E well below industry average
  • Increasing volume and cash‑rich balance sheet

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Strategic partnership extensions and buyback program
  • Ongoing margin pressure and revenue contraction
  • Potential for operational turnaround as cash flow remains solid

Key Metrics & Analysis

Financial Health

Revenue Growth-2.50%
Profit Margin-2.15%
P/E Ratio18.0
ROE-2.25%
ROA-0.87%
Debt/Equity10.17
P/B Ratio2.8
Op. Cash Flow$105.8M
Free Cash Flow$63.7M
Industry P/E38.2

Technical Analysis

TrendBullish
RSI44.3
Support$28.49
Resistance$40.49
MA 20$34.62
MA 50$31.42
MA 200$27.30
MACDBearish
VolumeIncreasing
Fear & Greed Index89.61

Valuation

Fair Value$41.50
Target Price$33.14
Upside/Downside3.57%
GradeUndervalued
TypeValue

Risk Assessment

Beta0.97
Volatility46.11%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.